Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma.
IOs
VEGF
VHL
ctDNA
mTOR
Journal
Clinical genitourinary cancer
ISSN: 1938-0682
Titre abrégé: Clin Genitourin Cancer
Pays: United States
ID NLM: 101260955
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
02
10
2018
revised:
10
12
2018
accepted:
08
01
2019
pubmed:
9
2
2019
medline:
14
4
2020
entrez:
9
2
2019
Statut:
ppublish
Résumé
Renal-cell carcinoma remains one of the elusive cancers that lacks a biomarker. It is the eighth most commonly diagnosed malignancy in the United States, and the incidence has slowly trended upward. In addition to the increase in newly diagnosed cases, the prevalence and overall survival of individuals with kidney cancer also has increased substantially. This formal review synopsizes the literature regarding the current treatment landscape, the utility of biomarkers in renal-cell carcinoma, and future directions regarding next-generation sequencing of circulating tumor DNA.
Identifiants
pubmed: 30733185
pii: S1558-7673(18)30712-2
doi: 10.1016/j.clgc.2019.01.004
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e454-e460Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.